Medtronic

TriMed Staff | | Cardiovascular Business | Patient Care
Medtronic (Booth 826) is featuring clinical research updates from its international RESOLUTE trials, designed to assess the safety and efficacy of its Endeavor Resolute drug-eluting stent (DES) system, which is an investigational device in the U.S., but commercially available in Europe.

Clinical research teams led by interventional cardiologists James Carr, MD, at East Texas Medical Center in the United States and Prof. Dr. Franz-Josef Neumann at the Heart Center of Bad Krozingen in Germany are enrolling patients in RESOLUTE US (R-US) and RESOLUTE International (R-Int), respectively. 

The Endeavor Resolute DES uses the proprietary BioLinx polymer, which was designed to meet the same biocompatibility requirements as the phosphorylcholine (PC) polymer used in Medtronic's Endeavor stent. Compared to the PC polymer, the BioLinx polymer is designed to extend the duration of drug exposure in the vessel.

TriMed Staff

Related Content

Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
FDA approves Medtronic’s new all-in-one mapping and ablation system for AFib

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.